Polypharmacy, drug-drug interactions and the pharmacology of ageing – Dr. Marta Boffito Welcome to your Polypharmacy, drug-drug interactions and the pharmacology of ageing – Dr. Marta Boffito Which of the following statements is true? a. Biktarvy is metabolised by cytochrome P450 b. Bictegravir is never a victim of drug-drug interactions c. Bictegravir is metabolised by approximately 50% by cytochrome P450 d. Raltegravir and bictegravir are identical drugs Which of the following statements is true?Raltegravir is:- a. A strong perpetrator of drug-drug interactions b. A novel non nucleoside reverse transcriptase inhibitor c. A victim of the interaction with rifampicin d. Dosed at 400mg once daily Which of the following statements is false> a. Unboosted integrase inhibitors are characterised by a low potential for drug-drug interactions b. Elvitegravir/cobicistat is a victim of the interaction with rifampicin c. Biktarvy should not be co-administered with rifabutin d. Raltegravir is mainly metabolised by UGT1A1 (UDP-glucuronosyltransferase) Which of the following statements is true?On the http://www.hiv-druginteractions.org website:- a. The red symbol means 'no clinically significant drug interaction expected' b. The amber (orange) symbol means 'potential interaction - may require close monitoring alteration of drug dosage or timing of administration' c. There are no green symbols d. The website does not exist Time is Up!